Literature DB >> 11169409

Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis.

C Bourquin1, A Iglesias, T Berger, H Wekerle, C Linington.   

Abstract

One strategy to reestablish self tolerance in autoimmune diseases is based on the use of DNA vaccination to induce ectopic expression of the target autoantigen. We assessed the potential of vaccination with a DNA construct encoding the myelin oligodendrocyte glycoprotein (MOG), an important candidate autoantigen in multiple sclerosis, to induce tolerance and protect against experimental autoimmune encephalomyelitis (EAE). Unexpectedly, mice vaccinated with MOG-DNA developed an exacerbated form of EAE when challenged with either MOG or an unrelated encephalitogen, myelin proteolipid protein. We demonstrate that this is due to the inability of DNA vaccination to tolerize the MOG-specific T cell response and to the concomitant induction of a cytopathic MOG-specific autoantibody response, which is pathogenic, enhancing demyelination, inflammation and disease severity. Our data suggest that tolerogenic strategies for autoimmune diseases based on DNA vaccination should be approached with caution, as the outcome is unpredictable.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11169409     DOI: 10.1002/1521-4141(200012)30:12<3663::AID-IMMU3663>3.0.CO;2-7

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

Review 1.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

3.  Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Dun Zhou; Rajneesh Srivastava; Stefan Nessler; Verena Grummel; Norbert Sommer; Wolfgang Brück; Hans-Peter Hartung; Christine Stadelmann; Bernhard Hemmer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

4.  Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein.

Authors:  Kevin C O'Connor; Heiner Appel; Lisa Bregoli; Matthew E Call; Ingrid Catz; Jennifer A Chan; Nicole H Moore; Kenneth G Warren; Susan J Wong; David A Hafler; Kai W Wucherpfennig
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

5.  Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders.

Authors:  Thomas Stahnke; Christine Stadelmann; Anne Netzler; Wolfgang Brück; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 6.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Proteomic strategies in multiple sclerosis and its animal models.

Authors:  Stella Elkabes; Hong Li
Journal:  Proteomics Clin Appl       Date:  2007-10-16       Impact factor: 3.494

8.  Role of B:T cell ratio in suppression of clinical signs: a model for silent MS.

Authors:  Lisa K Peterson; Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  Exp Mol Pathol       Date:  2008-04-08       Impact factor: 3.362

Review 9.  Emerging immunopharmacological targets in multiple sclerosis.

Authors:  Mojtaba Farjam; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  J Neurol Sci       Date:  2015-09-14       Impact factor: 3.181

10.  Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination.

Authors:  Hans-Christian von Büdingen; Stephen L Hauser; Antje Fuhrmann; Cameron B Nabavi; Joy I Lee; Claude P Genain
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.